Aizen Therapeutics

Aizen Therapeutics is an artificial intelligence-driven biotechnology company that has pioneered Mirror Peptides, a new class of biologic drugs. Mirror Peptides are synthetic all-D amino acid peptides, representing a vast, untapped therapeutic chemical space that offers enhanced therapeutic stability and reduced exogenic immunogenicity for patients. Aizen discovered these mirror peptides through a proprietary AI protein design platform developed by Dr. David Van Valen, a professor at the California Institute of Technology. Backed by life science venture capital, Aizen, headquartered in San Diego, California's biotech hub, is advancing a diversified portfolio of therapies targeting neurological disorders, solid tumor cancers, and genetic diseases.